2011
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
Komaki R, Blumenschein G, Wistuba I, Lee J, Allen P, Wei X, Welsh J, O'Reilly M, Herbst R, Tang X, Meyn R, Liu D, Hong W. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. Journal Of Clinical Oncology 2011, 29: 7020-7020. DOI: 10.1200/jco.2011.29.15_suppl.7020.Peer-Reviewed Original Research
2005
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response
Lu C, Komaki R, Herbst R, Evans W, Lee J, Truong M, Moore C, Choy H, Bleyer A, Fisch M. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. Journal Of Clinical Oncology 2005, 23: 7144-7144. DOI: 10.1200/jco.2005.23.16_suppl.7144.Peer-Reviewed Original Research
2003
O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response
Lu C, Komaki R, Herbst R, Evans W, Smith T, Moore C, Kolbye S, Choi N, Choy H, Bleyer A. O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response. Lung Cancer 2003, 41: s90. DOI: 10.1016/s0169-5002(03)91969-6.Peer-Reviewed Original Research